Efficacy of the Intravitreal Bevicizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy

Purpose: To determine the efficacy of bevicizumab in the treatment of vitreous hemorrhage in proliferative diabetic retinopathy. Material and Method: The hundred patients with type I and type II diabetes mellitus for more than 7 to 8 years and having New vessels at the disc (NVD) or elsewhere on the fundus (NVE) were collected from Mayo hospital outpatient department. After taking informed consent and recording the demographic details including name, age, sex, address etc patients were admitted in ward of Eye unit I for injection bevicizumab (Avestin). Patients were evaluated and graded by directly taking the fundus picture and B-scan. Patients were examinned second week and finally on the fourth week by again directly taking the fundus photograph and doing the B – scan for assessing the efficacy of bevicizumab. Results: Intravitreal Avastin reduced the vitreous hemorrhage in 39% of patients while in 61% of patients it was not successful in suppressing the vitreous hemorrhage. Conclusion: Intravitreal Avastin reduced the chance of the vitreous hemorrhage and hence improved the vision and significantly prevented the patients from the massive surgical procedure of vitrectomy.